Formulation, Development & Delivery In-Depth Focus 2021

In this in-depth focus, experts discuss why nanoparticles are a promising alternative for delivering inflammatory bowel disease therapies and highlight the potential of antibody-drug conjugates to advance oncology treatment.

Formulation, Development & Delivery

    To read this in-depth focus in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Catalent

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    • Nanoparticles for drug delivery: next-generation biological drugs to treat inflammatory bowel diseases
      Nanoparticles offer a promising alternative to conventional drug delivery that allow for more precise targeting and controlled release. Here, Dr Fabrice Navarro discusses the benefits of these nanocarriers and their potential as a therapy for inflammatory bowel diseases (IBDs).
    • Antibody-drug conjugates: challenges, solutions and future potential
      The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.